|
|
|
|
|
Keynote speakers included Erminia "Mimi" Guarneri, M.D., F.A.C.C., founder and medical director of the Scripps Center for Integrative Medicine, and Judy Norsigian, co-author of Our Bodies, Our Selves.
|
 |
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
 Michelle Berlin and Lillian Shirley
|
|
|
 |
|
In 2004, the OHSU Center for Women’s Health established Policy Advisory Toward Health (PATH) for women. PATH for women provides accurate, evidence-based data for health policy issues about women's health to policymakers and other key stakeholders. PATH for women has become a regional and national resource for national and regional legislators, health professionals, health policy advocates and the community at large. PATH for women serves policymakers as the premier evidence-based women’s health policy group for Oregon and beyond.
. |
|
Dr. Cain |
|
The National Cancer Institute (NCI) has issued an announcement encouraging treatment with anticancer drugs via two methods for women with advanced ovarian cancer. The combined methods, which deliver drugs directly into the abdomen, extend survival for women with advanced ovarian cancer by about a year. OHSU participated in the NCI-supported clinical trial that led to the announcement.
"This is exciting news for women with ovarian cancer, and it lives out a promise for intraperitoneal therapy that for about 20 years has been hoped for," said Joanna M. Cain, M.D., professor and chairwoman of obstetrics and gynecology in the OHSU School of Medicine and director of the OHSU Center for Women's Health and member of the OHSU Cancer Institute.
. |
|
Dr. Cappuccini
|
|
A new targeted, "silver bullet" drug is being given to women with ovarian cancer as part of a new study by Fabio Cappuccini, M.D., OHSU Center for Women's Health researcher and surgical oncologist.
The drug, Telcyta, has been shown in animal studies to be effective in fighting ovarian cancer in subjects that are resistant to platinum, one of the best drugs to combat ovarian cancer. Fabio Cappuccini, M.D., principal investigator, described how Telcyta works: "The platinum drug is like the quarterback and Telcyta acts like a defensive lineman..."
. |
|
Dr.
Guise |
|
OHSU and NASA's new study, "Using Military and Aviation Simulation Experience to Improve Rural Obstetric Care," is very down-to-earth and will help reduce errors in emergency, high-risk births. The technology used to train astronauts is being applied to simulation of obstetric emergencies via use of a high-tech pregnant manikin that will be programmed to give birth during various life-threatening emergencies.
The goal of this project according to Jeanne-Marie Guise, M.D., M.P.H., the principal investigator, is to bring the space agency's simulation technology and training into the field of obstetrics. OHSU was awarded the $480,000, two-year grant which will be used to develop a standardized curriculum at OHSU and tested in several rural hospitals in Oregon.
. |
|
 |
|
April 8, Doubletree Inn, Portland, Oregon
This conference will be a time for those working to reduce violence against women and children to gather and share their innovative work. Collaborations among health and human service providers, violence prevention/intervention advocates, and communities will be underscored. Come to hear what is going on in this important work in women's health!
. |
|
|
|
|
|
Dr. Nedrow |
|
.
. |
|
|
|
|
|
 |
|
|
|
 |
|
|
|
 |
|
|
|
|
OHSU
Notice of Privacy Practices